香港屈臣氏推護膚產品推薦功能Skinfie Lab 料明年推展至東南亞
屈臣氏集團宣佈,與歐萊雅的科技應用公司ModiFace攜手開發創新皮膚分析功能「Skinfie Lab」,將率先於香港屈臣氏推出,並計劃在2023年初前陸續擴展至泰國、臺灣、菲律賓、新加坡、馬來西亞及印尼屈臣氏。
集團表示,Skinfie Lab用人工智能技術,透過分析用戶自拍照可提供個人化的護膚產品推薦,涵蓋所有品牌達10,000款產品。屈臣氏集團亞洲首席數碼總監吳逸羣表示,相信該功能將會改變顧客購買護膚產品的模式,未來會繼續致力運用先進科技來開發創新技術方案,爲顧客提供無縫O+O購物體驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.